


QUESTION	KNOWLEDGE	PASS CRITERIA
<p>1.</p> <p>a. With regard to drugs, what is “potency”.</p> <p>b. How is this different to Efficacy?</p> <p>c. Draw a concentration-response curve showing 2 drugs with the same potency but different efficacy.</p>	<p>Potency refers to the affinity or attraction between an agonist and its receptor.</p> <p>A good measure of drug potency is the EC_{50} – the concentration that produces 50% of the maximal response.</p> <p>Efficacy is the maximal response that a drug (agonist) can produce (E_{max}) when all receptors are occupied, irrespective of the concentration required to produce that response.</p> 	<p>Demonstrate understanding of efficacy and potency.</p>

<p>2. a. Describe the mechanism of action of glyceryl trinitrate.</p> <p>b. What are the clinical effects of nitrates</p>	<ul style="list-style-type: none"> • Taken up by vascular smooth muscle • Interacts with tissue sulfhydryl groups • Releases free radical nitric oxide • Activates cGMP • Dephosphorylates myosin light chains • Reduces intracellular Ca levels • Smooth muscle relaxation & vasodilation <ul style="list-style-type: none"> • Low doses – venodilation ⇒ ↓ preload & stroke volume • Higher doses – arterial dilation ⇒ ↓ blood pressure <p>⇒ ↓ cardiac output & ↓ myocardial oxygen demand</p> <p>+ dilation of coronary arteries/redistribution of perfusion</p> <p>⇒ improved oxygen delivery to myocardium & resolution of ischaemic pain</p> <p>[Prompt if needed “What other clinical effects may be seen?”]</p> <ul style="list-style-type: none"> • Adverse effects: postural hypotension, tachycardia, dizziness, headache, flushing, blurred vision, dry mouth, rash 	<p>Must state</p> <ul style="list-style-type: none"> • vascular smooth muscle • nitric oxide • vasodilation <p>Must state</p> <ul style="list-style-type: none"> • ↓ BP • ↓ myocardial oxygen demand • 2 listed other effects
<p>3. a. What is pancuronium?</p>	<p>Non-depolarising NM blocker Quaternary ammonium compound Potent competitive antagonist of ACh at nicotinic receptors skeletal muscle motor end-plate Interruption of transmission requires > 70% occupancy; blockade requires > 95% occupancy</p>	<p>Nondepolarising NM blocker</p>

<p>b. Describe the pharmacokinetics of pancuronium?</p> <p>c. What are the adverse effects of pancuronium?</p>	<p>Poorly absorbed after oral admin Rapidly and widely distributed after iv Rapid elimination ($T_{1/2}$ 30min) by urinary excretion unchanged drug (highly water soluble), and hepatic metabolism with biliary excretion [Prompt: Describe its distribution and elimination]</p> <p>Uncommon Minor tachycardia, hypertension, sl \uparrow CO can occur Life-threatening anaphylaxis < 1:10,000</p>	<p>Rapid distribution Rapid elimination</p> <p>A cardiac and allergy effect</p>
<p>4. a. Describe the pharmacokinetics of lithium</p> <p>b. What are the adverse effects of Lithium at therapeutic levels?</p> <p>c. What are the signs/symptoms of lithium toxicity?</p>	<p>Rapidly absorbed (except SR preparations) with peak plasma concs in 1-3hrs. High bioavailability. Not metabolised Renally excreted unchanged with partial reabsorption from PT. Long $T_{1/2}$ of 24hrs in adults Steady state plasma concs not reached for 5-7 days</p> <p>(PROMPT – How long does it take to reach steady state plasma conc?)</p> <p>Tremor, nausea, polydypsia /polyuria, diarrhoea, weight gain. Long-term: Acne / psoriasis, hypothyroidism, nephrogenic diabetes insipidus (inhibits the effect of ADH on the DT cells -> polyuria).</p> <p>GIT: Vomiting. Neuro: Tremors, confusion, slurred speech, ataxia, drowsiness, blurred vision, seizures.</p>	<p>Long $T_{1/2}$ so steady state plasma concs not reached for days. Renally excreted unchanged.</p> <p>Polyuria & Polydipsia OR NDI.</p> <p>CNS effects with at least 3 symptoms</p>

<p>5. a. List the advantages of eye ointments over eye drops.</p>	<p>More stable Less absorption into lacrimal ducts Longer retention time on conjunctival surface Safer with potent drugs Ointment bases provide protection and comfort at night</p>	<p>2 to pass</p>
<p>b. List by action the types of drugs used topically in the eye</p>	<p>Mydriatics Miotics Cycloplegics Decongestants Antibiotics Antivirals Antiseptics Corticosteroids Local anaesthetics Stains eg. Fluorescein</p>	<p>4 to pass</p>
<p>c. List the ideal properties of an ocular local anaesthetic</p>	<p>Quick onset of action (10-20 secs.) Useful duration of action (10-20 mins) No obvious effects on function or healing No interactions with drugs used concurrently</p>	<p>Quick onset and useful duration of action</p>

QUESTION	KNOWLEDGE	PASS CRITERIA
<p>1.</p> <p>a. What routes of drug administration are there?</p> <p>b. What factors affect the rate of drug absorption from the small intestine?</p> <p>c. What are potential disadvantages of rectal drug administration?</p>	<p>Enteral: Sublingual, buccal, oral, rectal Parenteral: SC, IM, IV, intrathecal, epidural Inhalational Topical</p> <p>Ionisation status of drug: alkaline Intestinal pH (7-8) favours absorption of un-ionised basic drugs Intestinal motility; increased motility lead to reduced transit time and drug absorption Gut surface area, blood flow, solubility of drug, formulation of drug</p> <p>PROMPT: What is a specific drug factor</p> <p>Erratic absorption because of rectal contents Local drug irritation Uncertainty of drug retention</p>	<p>Enteral/oral + 3 non-enteral</p> <p>Must mention drug factors and gut factors</p> <p>1/3</p>
<p>2.</p> <p>a. Describe the mechanism of action of ACE inhibitors</p> <p>b. What are the adverse effects of ACE inhibitors</p>	<ul style="list-style-type: none"> • competitive block conversion of angiotensin I to II ⇒ <ul style="list-style-type: none"> ○ decreased vascular tone from prevention of vasoconstrictor effects of Ang II (main effect) ○ inhibition of aldosterone secretion caused by Ang II leading to reduced Na & H₂O resorption ⇒ decreased BP • dizziness, hypotension • headaches, weakness • loss of taste, nausea, diarrhoea • rash, fever, joint pain • cough • mild hyperkalaemia due to decrease in aldosterone secretion • acute renal failure 	<p>3 in bold to pass</p> <ul style="list-style-type: none"> • hypotension or dizziness • cough • plus 2 others

<p>c. What are some drug interactions that occur with ACE inhibitors</p>	<ul style="list-style-type: none"> • Diuretics ⇒ hypotension • General anaesthetics ⇒ hypotension • Lithium ⇒ lithium toxicity • NSAIDS ⇒ hyperkalaemia & reduced effects of ACE inhibitor • Potassium sparing diuretics / potassium supplements ⇒ hyperkalaemia 	<p>2 to pass</p>
<p>3.</p> <p>a. What is the mechanism of action of erythromycin?</p> <p>b. What is the mechanism for the drug interactions associated with erythromycin & give some examples?</p> <p>c. What are the adverse effects of erythromycin?</p>	<p>Inhibits RNA-dependent protein synthesis by binding to the 50S ribosomal subunit. Bacteriostatic (at high conc with selected organisms can be bactericidal)</p> <p>Inhibits hepatic CYP3A4. Usually inhibits metabolism of other drugs metabolism causing increased activity.</p> <p>Examples: benzodiazepines, carbamazepine, cisapride (cardiotoxicity), digoxin, warfarin, theophylline, cyclosporine, tacrolimus</p> <p>Common: GIT: abdo cramp, diarrhoea, N&V, candida (oral,vag) Rare: hypersensitivity, hearing loss, pancreatitis, hepatotoxicity Rapid iv may cause ventric arrhythmias.</p>	<p>Protein synthesis inhibitor Bacteriostatic</p> <p>Inhibit hepatic metabolism</p> <p>One example</p> <p>GIT plus another</p>
<p>4.</p> <p>a. Describe the pharmacokinetics of phenytoin.</p>	<p>Oral absorption slow and variable: Time to peak levels 1.5-3hrs. Saturable hepatic metabolism leading to non-linear PK and variable T_{1/2} of 7-42hrs. Metabolites excreted in the bile & urine.</p>	<p>Saturable metabolism/non-linear pharmacokinetics</p>

<p>b. What are the adverse effects of phenytoin?</p>	<p>Idiosyncratic: hirsutism, gingival hyperplasia & overgrowth with bleeding, acne & facial coarsening.</p> <p>Dose related neurotoxic effects: drowsiness, dizziness, blurred vision, hallucinations, slurred speech, clumsiness, dizziness and confusion.</p> <p>Rapid IV administration associated with CV collapse.</p> <p>PROMPT: Are there any specific problems with IV administration.</p>	<p>Dose-related CNS effects Cardiac with IV administration & 1 other.</p>
<p>5. a. What are the indications for benzodiazepine use?</p> <p>b. Explain the rationale for use of benzodiazepines in alcohol withdrawal</p>	<p>Anxiety Disorders Preoperative Medication Insomnia Sleep Disturbances Seizure Disorders Panic Disorder Alcohol Withdrawal Muscle Spasm Induce amnesia during cardioversion/endoscopic procedures</p> <p>Down-regulation of neuro-inhibitory GABA receptors in alcohol dependent individual leads to symptoms of GABA deficiency in withdrawal. BZD act at a modulatory site on the the GABA_A receptor to facilitate GABA binding to the GABA_A receptors, enhance chloride channel opening, and overcome neuroexcitatory symptoms of GABA deficiency.</p>	<p>Seizures and 2 others</p> <p>Facilitate GABA binding to the GABA_A receptors Control neuroexcitatory symptoms of alcohol withdrawal.</p>

QUESTION	KNOWLEDGE	PASS CRITERIA
<p>1.</p> <p>a. What is meant by Total Body Clearance” of a drug</p> <p>b. Name 2 drugs that have a high hepatic clearance and explain why this is important.</p> <p>c. What factors determine drug half-life</p>	<p>Describes the ability of the body to eliminate a drug. It refers to the theoretical volume of plasma emptied of drug per unit time (usually L/h). Total body clearance reflects the sum of all clearance process including renal, hepatic and other.</p> <p>Lignocaine, Morphine, Propranolol, Pethidine.</p> <p>Drugs with high hepatic elimination may only be suitable for parenteral administration or have significant dosing variations depending on the route of administration.</p> <p>PROMPT: How might it impact on route of administration</p> <p>Volume of Distribution and Clearance ($t_{1/2} = 0.693 \times Vd / Cl$) Vd and clearance change with disease states - cardiac, hepatic and renal failure</p>	<p>Definition</p> <p>2 drugs</p> <p>Demonstrate understanding</p> <p>Vd and clearance</p>
<p>2.</p> <p>a. What are the pharmacokinetic properties of frusemide?</p> <p>b. What are the site and mechanism of action of frusemide ?</p>	<ul style="list-style-type: none"> • Rapid absorption after oral admin • Oral bioavailability 50% (range 10 –100%) • Highly protein-bound (>95%) • 50% conjugated in kidney & 50% excreted in urine unchanged (tubular secretion) • Elimination $t^{1/2}$ 1.5 – 2 hours • Peak effect 30 minutes IV / 1 hour oral • Actively secreted into lumen of nephron from proximal tubule cells via organic-base pump • Inhibits $Na^+ - K^+ - 2Cl^-$ transporter in thick ascending limb of loop of Henle thus preventing resorption of Na^+ & Cl^- • Abolishes counter-current concentrating mechanism leading to a dilute urine 	<p>Must list 3 properties</p> <p>Must mention thick ascending limb of loop of Henle and reduced resorption of Na and Cl.</p>

<p>C. What are the adverse effects of the frusemide?</p>	<ul style="list-style-type: none"> • Electrolyte disturbances – hypokalemia, hyponatraemia, hypomagnesaemia, hyperuricaemia • Postural hypotension & dizziness • Increased LDL & triglycerides, decreased HDL • Ototoxicity (high dose IV) • Drug interactions 	<p>Must list</p> <ul style="list-style-type: none"> • Hypokalemia • Hyponatremia • Hypotension or dizziness • 1 other
<p>3. a. What is the mechanism of action of cephalosporins</p> <p>How does the spectrum of microbiological activity for the 4th generation cephalosporins compare to that of earlier generations?</p> <p>What is the relationship between penicillin allergy and cephalosporin allergy.</p>	<p>Inhibit bacterial cell wall synthesis, cell division and growth (similar to penicillins) Bactericidal Most effective in rapidly dividing cells.</p> <p>Gram negative as for 3rd generation e.g. E Coli, H Influenza, Klebsiella Some gm positive (S Pneumonia) but less than 1st generation More resistant to B Lactamases than earlier generations</p> <p>5-15% possibility of cross-reaction with penicillin allergy.</p>	<p>Bolded material</p> <p>Bolded material</p> <p>Aware of cross-reactivity</p>
<p>4. a. Describe the general pharmacokinetic characteristics of antipsychotic drugs</p>	<p>Most are readily but incompletely absorbed. Many undergo significant first pass metabolism Most are lipid soluble (lipophilic) Most have high PPB (92-99%) Most are completely metabolised by hepatic enzymes (oxidation; demethylation) These are catalysed by liver enzymes.</p> <p>PROMPT: Use chlorpromazine as an example</p>	<p>Lipid soluble. Hepatic metabolism + 1 other</p>

<p>Define the term “atypical” antipsychotic and provide an example.</p> <p>c. Describe the adverse drug reactions to olanzapine.</p>	<p>Newer antipsychotic agents with less propensity to cause extrapyramidal side-effects. Better at treating negative features of schizophrenia.</p> <p>They share a greater ability to alter 5HT_{2A} receptor activity than to interfere with D₂-receptor action.</p> <p>Examples: olanzapine; clozapine; quetiapine; risperidone; loxapine</p> <p>Weight gain Sedation (but less than typical antipsychotics) Minor orthostatic hypotension Minor anticholinergic effects (dry mouth, urine retention etc) (Extrapyramidal effects less prominent)</p>	<p>Less EPS One example</p> <p>2 effects</p>
<p>5.</p> <p>a. What is the mechanism of action of flumazenil?</p> <p>b. What are the indications for flumazenil use</p> <p>c. What potential problems should be anticipated when using flumazenil?</p>	<p>Antagonist at the BZD binding site on the GABA_A receptor (ligand-gated chloride channel). Decreases the binding of GABA. Blocks GABA-induced increase in Cl⁻ permeability and influx of Cl⁻ into the cell causing hyperpolarisation and decreased excitability of the neuron.</p> <p>Avoid intubation or ICU admission in BZD overdose. Reverse BZD sedation after procedures Diagnostic role</p> <p>Precipitate seizures in mixed overdoses with BZD and proconvulsants Precipitate seizures in pts taking BZD to control epilepsy Precipitate withdrawal symptoms and seizures in BDZ-dependent Duration of action is only 1-3hrs thus repeated administration may be necessary Reversal of BZD-induced respiratory depression has not been demonstrated, so resp and cardiovasc support may be required Adverse Effects: headache, visual disturbance, increased anxiety, nausea, light-headedness</p>	<p>Specific BZD receptor antagonist at GABA receptor</p> <p>Reverse the sedative effects of BZD</p> <p>Precipitate fits Need for repeated doses</p>

